BERG Presents Data Uncovering a Novel Contributor to Parkinson’s Disease at Society for Neuroscience 2016 Meeting

BERG Presents Data Uncovering a Novel Contributor to Parkinson’s Disease at Society for Neuroscience 2016 Meeting BERG Interrogative Biology® Platform Identifies Potential Contributor to LRRK2-mediated Cell Death in Parkinson’s Disease BOSTON, November 14, 2016 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today unveiled data from a recent study that clarified…

BERG, The Icahn School of Medicine at Mount Sinai to host “Fast Track” event at Fast Company’s Second Annual Innovation Festival 2016

BERG, The Icahn School of Medicine at Mount Sinai to host “Fast Track” event at Fast Company’s Second Annual Innovation Festival 2016 Leading players at the forefront of healthcare innovation will discuss how emerging technologies are delivering on the promise of precision medicine BOSTON – October 31, 2016 — BERG, a biopharmaceutical company uncovering health…

BERG Strengthens Financial Leadership And Expands Board Of Directors

BOSTON, Aug. 17, 2016 /PRNewswire/ — BERG, a technology-based biopharmaceutical company uncovering health solutions through a data-driven, systems biological research approach, today announced an expansion of its Board of Directors, adding three new members who bring a wealth of healthcare, financial and executive leadership to the company. The additions to BERG’s Board of Directors include Shumeet…

BERG Announces Clinical Trial Data Presentations Of BPM 31510 In Advanced Solid Tumors And BPM 31543 For Prevention Of Chemotherapy-Induced Alopecia At American Society of Clinical Oncology Annual Meeting

BOSTON, June 5, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it will present two poster presentations on the Phase 1 study of BPM 31510 (IV) in advanced solid tumors and BPM 31543 for the prevention of chemotherapy-induced alopecia at the American Society of…

BERG Initiates Phase II Combination Trial Of BPM 31510 And Gemcitabine In Patients With Pancreatic Cancer

BOSTON, April 27, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase II clinical trial for its drug candidate BPM 31510 in combination with gemcitabine for the potential treatment of pancreatic cancer. The primary objective of the trial is to evaluate…

BERG Announces BPM31510 Data Presentations At 2016 AACR Annual Meeting

BOSTON, April 18, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced five poster presentations showing new promising preclinical pancreatic cancer data, including new biomarkers for detection and improved treatment outcomes via the combination of BPM31510 with gemcitabine. Additionally new data demonstrates molecular drivers of endothelial cell…

BERG Appoints Michael A. Kiebish As Chief Precision Medicine Officer

New CPMO position spotlights growing importance of precision medicine in disease treatment Feb 23, 2016, 09:04 ET from BERG BOSTON, Feb. 23, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced the appointment of Michael A. Kiebish, Ph.D. as Chief Precision Medical Officer.  In the newly created role, Kiebish will…

BERG Appoints Narain To Chief Executive Officer; Haddock Joins As Chief Financial Officer/ Chief Operating Officer

BERG Hires Bristol-Myers Squibb Former Head of Finance Feb 09, 2016, 09:02 ET from BERG BOSTON, Feb. 9, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, has announced the appointment of Jason Haddock as Chief Financial Officer and Chief Operating Officer. Haddock brings to BERG over 20 years of experience in corporate…

Berg Joins U.K. Prime Minister’s Initiative, Genomics England to Sequence 100,000 Genomes

Boston based biotech company to apply its analytics platform to GENE Consortium data Sep 30, 2015, 10:23 ET from Berg BOSTON, Sept. 30, 2015 /PRNewswire/ — Berg, a Boston-based biopharmaceutical company at the forefront of precision medicine, today announced it will join an industry collaboration with Genomics England. Formed by U.K. Prime Minister David Cameron, Genomics England is partnering with innovative…

National Institutes of Health to Evaluate Berg’s Drug for the Treatment of Kidney Cancer

BOSTON, Sept. 8, 2015 — Berg, a Boston-based biopharmaceutical company, has announced that it has entered into a Materials-Cooperative Research and Development Agreement (M-CRADA) with the United States National Institutes of Health (NIH) for the treatment of kidney cancer. Dr. W. Marston Linehan, Chief of Urologic Oncology at the Center for Cancer Research at the National Cancer…
1 2 3